Brief: FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application For Phase 2 Study Of Oral Tnf-Α Inhibitor Mymd-1
14/08/2023 14:15
Aug 14 (Reuters) - MyMD Pharmaceuticals Inc MYMD.O :
* FDA ACCEPTS MYMD PHARMACEUTICALS’ INVESTIGATIONAL NEW DRUG
APPLICATION (IND) FOR PHASE 2 STUDY OF ORAL TNF-Α INHIBITOR
MYMD-1® IN RHEUMATOID ARTHRITIS (RA)
* MYMD PHARMACEUTICALS - ADVANCING 3 CLINICAL PROGRAMS FOR
MYMD-1
IN CHRONIC INFLAMMATORY CONDITIONS INCLUDING SARCOPENIA, RA &
HASHIMOTO'S THYROIDITIS
Source text for Eikon: ID:nBw25y2N7a
Further company coverage: MYMD.O
((Reuters.Briefs@thomsonreuters.com;))